TIDMVAL
RNS Number : 4280E
ValiRx PLC
04 July 2019
VALIRX PLC
("ValiRx", the "Company" or the "Group")
UPDATE RE VAL301
FOR THE TREATMENT OF ENDOMETRIOSIS
"ValiRx progresses VAL301 Clinical Development Plan"
London, UK., 04 July 2019: ValiRx Plc (AIM: VAL), the clinical
stage biotechnology company, is pleased to announce that the
Company's clinical team has signed an agreement to work with Aptus
Clinical Ltd ("Aptus"), the UK based, clinical Contract Research
Organisation ("CRO"), to effectuate a clinical development plan for
VAL301 incorporating a Phase I/II study design concept in
Endometriosis.
Aptus will be working with ValiRx on regulatory, technical and
scientific areas, in order to bring VAL301 nearer to the
clinic.
Endometriosis is a benign, oestrogen -dependent chronic
condition, characterised by endometrial tissue growth outside of
the uterus. Symptoms including heavy painful periods, pain with
intercourse and infertility are often severe and are associated
with a decreased quality of life for young women. The condition
affects an estimated 1 in 10 women during their reproductive years,
equating to approximately 176 million women worldwide*, posing a
high economic burden.
VAL301 is derived from the same active pharmaceutical ingredient
as VAL201, which is currently in a Phase I/II clinical trial where
the compound has demonstrated safety and has been well tolerated.
These positive results will be used to strengthen the clinical
application of the development programme. Pre-clinical studies
indicate that treatment with VAL301 should not affect bone density
or fertility, two of the major problems associated with current
medical treatments for endometriosis. ValiRx intends to develop
VAL301 as a non-invasive, effective and better tolerated treatment
for this debilitating condition.
*Source: https://www.ncbi.nlm.nih.gov/pubmed/30026507
Dr Satu Vainikka, CEO of ValiRx, commented: "Our agreement with
Aptus represents an important stage in preparing the VAL301
compound for clinical study. I look forward to VAL301's future
development and its potential to benefit women who suffer from this
extremely painful condition".
Dr Steve McConchie, Co-founder & CEO of Aptus, added: "We
are delighted to have been selected by ValiRx to work on the
development plan options for VAL301 in endometriosis. We look
forward to exploring some innovative opportunities with the team in
order to optimise the programme delivery timelines and progress
this important potential treatment rapidly to patients".
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
*** ENDS ***
For more information, please contact:
ValiRx plc Tel: +44 (0) 20 3008 4416
www.valirx.com
Dr Satu Vainikka, Chief Executive Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications. Tel: +44 (0) 7879 458
364
tarquin.edwards@valirx.com
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213 0880
Adviser)
Liam Murray / Jo Turner / Ludovico
Lazzaretti
Novum Securities Limited Tel: +44 (0) 20 7399 9400
Colin Rowbury
Notes for Editors
About Aptus
Aptus is a UK based, clinical CRO with particular expertise in
oncology, rare diseases and advanced (cell and gene) therapies. The
company provides design, set-up, management and monitoring of early
phase clinical trials. In addition, it supports clients with a
range of specialist services that include quality management
frameworks, clinical governance support and a number of digital
solutions that facilitate data storage, analysis and
visualisations.
Aptus are partners in iMATCH (innovate Manchester Advanced
Therapy Centre Hub), a consortium of experts from industry,
academia and the NHS, funded by Innovate UK. The iMATCH objective
is to accelerate the safe and effective delivery of advanced
therapies to increasing numbers of patients within the NHS. Aptus
are also preferred suppliers to the Cell and Gene Therapy
Catapult.
About ValiRx
ValiRx is a biotechnology oncology focused company specialising
in developing novel treatments for cancer and associated
biomarkers. It aims to make a significant contribution in
"precision" medicine and science, namely to engineer a breakthrough
into human health and well-being, through the early detection of
cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing
therapeutic candidates early in the development process. By aiming
for early-stage value creation, the company reduces risk
considerably while increasing the potential for realising value.
The group is already in licensing discussions with major players in
the oncology field.
ValiRx's two classes of drugs in development, which each have
the potential for meeting hitherto unmet medical needs by existing
methods, have worldwide patent filings and agreed commercial
rights. They originate or derive from World class institutions,
such as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents,
such as chemotherapy. With the development of target-based agents,
primed to attack cancer cells only, less toxic and more effective
treatments are now possible. New drugs in this group-such as those
in ValiRx's pipeline-promise to greatly improve outcomes for cancer
patients.
The Company listed on the AIM Market of the London Stock
Exchange in October 2006 and trades under the ticker symbol:
VAL.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCBRGDRXSGBGCX
(END) Dow Jones Newswires
July 04, 2019 02:00 ET (06:00 GMT)
Valirx (LSE:VAL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Valirx (LSE:VAL)
Historical Stock Chart
From Apr 2023 to Apr 2024